<DOC>
	<DOCNO>NCT01693471</DOCNO>
	<brief_summary>The objective study investigate influence HR-QOL ( SF-36 v2 ) result compliance MUCODYNE Tablets MUCODYNE DS ( Dry Syrup ) 50 % asthma patient whose control level partly control uncontrolled .</brief_summary>
	<brief_title>Survey Effect Health Related Quality Life ( QOL ) Associated With Compliance Carbocisteine Asthma Patients</brief_title>
	<detailed_description>Period : 2012-2013 Observation Time : 0 week , 4 week Matters investigate : 1 . QOL determination use SF-36 v2 2 . Medication compliance ( VAS scale ) 3 . Gender , age , diagnosis , asthma subtype , severity , duration disease , level asthma control , concomitant drug , comorbidities , smoking , alcohol , work</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Carbocysteine</mesh_term>
	<criteria>Male female patient â‰¥ 20 year age Outpatients Patients mild moderate persistent asthma Patients phlegm Patients whose level asthma control partly control uncontrolled Patients plan treat MUCODYNE Patients voluntarily submit write consent form upon participation study Patients history adverse reaction carbocisteine Patients serious cardiac , hepatic , renal , pulmonary , hematological disease Patients possibility pregnancy suspect pregnancy Patients complication malignancy Current smoker Patients definitive diagnosis COPD Other patient investigator subinvestigators consider inappropriate participate study</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>asthma</keyword>
	<keyword>SF-36</keyword>
	<keyword>HRQOL</keyword>
</DOC>